drug
cabotegravir LA
Marketedupdated 5mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval22 co-mentions · 11 sources
- drugcabotegravir + rilpivirine LA13 co-mentions · 13 sources
- tagInfectious Disease6 co-mentions · 6 sources
- companyViiV Healthcare Company4 co-mentions · 4 sources
- companyViiV Healthcare UK Ltd4 co-mentions · 4 sources
- company$GLAXFGSK plc2 co-mentions · 2 sources
- company$GSKGSK plc2 co-mentions · 2 sources
- drugcabotegravir sodium2 co-mentions · 2 sources
all catalysts(2)
Trials studying cabotegravir LA
- phase3Improving HIV-1 Control in Africa With Long Acting Antiretrovirals
- phase4A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
- phase4SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
- phase4Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
- phase3Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
- phase3Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
- phase1Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
- —Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 30, 2027
262 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (20)
- Jul 18, 2038method-of-use (U-3348)US 12178815
- Jul 18, 2038method-of-use (U-3348)US 12178815
- Apr 13, 2032formulationUS 11389448
- Apr 13, 2032formulationUS 11389448
- Nov 27, 2031method-of-use (U-3348)US RE50189
- Nov 27, 2031method-of-use (U-3348)US RE50189
- Sep 15, 2031formulationUS 112245974.9y
- Sep 15, 2031formulationUS 112245974.9y
- Sep 15, 2031formulationUS 112245974.9y
- Sep 15, 2031formulationUS 121382644.9y
- Sep 15, 2031formulationUS 121382644.9y
- Sep 15, 2031formulationUS 121382644.9y
- Feb 4, 2031compositionUS 84101034.3y
- Feb 4, 2031compositionUS 84101034.3y
- Feb 4, 2031compositionUS 84101034.3y
- Jun 30, 2027method-of-use (U-3405)US 11389447262d
- Jun 30, 2027method-of-use (U-3405)US 11389447262d
- Apr 28, 2026compositionUS 10927129
- Apr 28, 2026compositionUS 10927129
- Apr 28, 2026compositionUS 10927129
FDA exclusivities (3)
- Jan 21, 2026NCENew Chemical Entity (5y)
- Jan 21, 2026NCENew Chemical Entity (5y)
- Jan 21, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that